Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

02 Jan, EOD - Indian

SENSEX 79943.71 (1.83)

Nifty 50 24188.65 (1.88)

Nifty Bank 51605.55 (1.07)

Nifty IT 44351.75 (2.26)

Nifty Midcap 100 58108.2 (1.14)

Nifty Next 50 69103.6 (1.25)

Nifty Pharma 23553.4 (0.40)

Nifty Smallcap 100 19080.35 (0.64)

02 Jan, EOD - Global

NIKKEI 225 39894.54 (-0.96)

HANG SENG 19852.41 (1.17)

S&P 5943.25 (0.25)

LOGIN HERE

Cancel

BSE Code : 532321 | NSE Symbol : ZYDUSLIFE | ISIN : INE010B01027 | Industry : Pharmaceuticals |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
27-Dec-2024	27-Dec-2024	Acquisitions	Update on acquisition of a business
30-Oct-2024	12-Nov-2024	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve unaudited financial results for the quarter and half year ended on September 30 2024. Unaudited financial results for the quarter and half year ended on September 30, 2024 Unaudited financial results for the quarter and half year ended on September 30, 2024 (As Per BSE Announcement Dated on 12.11.2024)
18-Jul-2024	09-Aug-2024	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2024. Unaudited Financial results for the quarter ended June 30, 2024 (As Per BSE Announcement dated on 09.08.2024)
09-May-2024	17-May-2024	Accounts	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve audited financial results for the quarter and year ended on March 31 2024 Final dividend The Board of Directors at their meeting held today have recommended final dividend of Rs.3.00/- (@300%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 9, 2024 Appointment of Independent Director (As Per BSE Announcement Dated on 17.05.2024)
29-Jan-2024	09-Feb-2024	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2024 inter alia to consider and approve Unaudited Financial Results for the quarter / nine months ended on December 31 2023. Buyback of shares Buyback of shares Record date of buyback: February 23, 2024 Unaudited financial results for the quarter and nine months ended on December 31, 2023 Buyback of shares (As Per BSE Announcement Dated on 09.02.2024) Newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter / nine months ended on December 31, 2023 in Financial Express on February 10, 2024. (As Per BSE Announcement Dated on 10.02.2024)
30-Oct-2023	07-Nov-2023	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve the unaudited financial results for the quarter / half year ended on September 30 2023. Unaudited Financial Results for the quarter / half year ended on September 30, 2023 Unaudited Financial Results for the quarter / half year ended on September 30, 2023 (As Per BSE Announcement Dated on 07.11.2023)
31-Jul-2023	11-Aug-2023	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve the unaudited financial results for the quarter ended on June 30 2023. Unaudited Financial Results for the quarter ended on June 30, 2023 Unaudited Financial Results for the quarter ended on June 30, 2023 (As Per BSE Announcement Dated on 11.08.2023)
12-May-2023	18-May-2023	Accounts	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2023 inter alia to consider and approve apart from other agenda items approval of audited financial results for the quarter / year ended on March 31 2023 and to recommend final dividend for the financial year ended on March 31 2023. Outcome of Board meeting Re-appointment of Independent Director of the Company (As per BSE Announcement Dated on 18/05/2023)
23-Jan-2023	03-Feb-2023	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve unaudited financial results for the quarter / nine months ended on December 31 2022. The Board of Directors at their meeting held today i.e. February 3, 2023, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter / nine months ended on December 31, 2022. (As per BSE Announcement Dated on 03/02/2023)
29-Nov-2022	29-Nov-2022	Change in Directors	Appointment of two Independent Directors
31-Oct-2022	11-Nov-2022	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve approval of unaudited financial results for the quarter / half year ended on September 30 2022. The Board of Directors at their meeting held today i.e. November 11, 2022, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter / half year ended on September 30, 2022. (As Per BSE Announcement dated on 11.11.2022)
03-Aug-2022	10-Aug-2022	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2022 Approval of the unaudited financial results for the quarter ended on June 30, 2022 (As Per BSE Announcement dated on 10.08.2022)
13-May-2022	20-May-2022	Accounts	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 inter alia to consider and approve The meeting of the Board of Directors of the Company will be held on Friday May 20 2022 to consider apart from other agenda items to approve the audited financial results for the quarter / year ended on March 31 2022 and to recommend final dividend for the financial year ended on March 31 2022 Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 ,inter alia, to consider and approve Update on board meeting. Board will also consider the proposal to buyback equity shares of the Company. With reference to the earlier letter dated May 13, 2022 intimating about the meeting of the Board of Directors of the Company scheduled to be held on May 20, 2022. Zydus Lifesciences Ltd has now informed BSE that the Board of Directors of the Company, at its aforesaid meeting, will also consider a proposal for buyback of fully paid-up equity shares of the Company and the matters necessary and incidental thereto, in accordance with the applicable provisions under the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws. (As Per BSE Announcement Dated on 17.05.2022) Board approves the dividend Intimation of Record Date Buy Back of Shares Annual Audited financial results for the financial year ended on March 31, 2022 (As Per BSE Announcement Dated on 20.05.2022) The Board of Directors at their meeting held today have recommended final dividend of Rs. 2.50/- (@ 250%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 10, 2022. Re-appointment of Deloitte as the Statutory Auditors subject to the approval of the shareholders at the ensuing annual general meeting (As Per BSE Bulletin Dated on 20.05.2022)
25-Jan-2022	03-Feb-2022	Quarterly Results	CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2022 inter alia to consider and approve Approval of the unaudited financial results for the quarter / nine months ended on December 31 2021 The unaudited financial results (standalone and consolidated) for the quarter / nine months ended on December 31, 2021 (As Per BSE Announcement dated on 03.02.2022)
21-Jan-2022	21-Jan-2022	Change in Directors	Re-appointment of Dr. Sharvil P. Patel as the Managing Director subject to approval of shareholders.

1 2

LOGIN HERE

Zydus Lifesciences Ltd

Board Meeting